This retrospective observational study was carried out to study the effect of USgHIFU ablation for uterine fibroids in women, including those with a history of infertility.

Overall, 560 females of reproductive age having uterine fibroids and underwent USgHIFU therapy considered. The pregnancy outcomes, for example, conception time, gestational age, delivery mode, neonatal outcomes and issues during pregnancy and delivery, were all noted.

There were 71 pregnancies (82% natural; 18% in vitro fertilized [IVF]) in 55 females following USgHIFU therapy. The median time to conception was 12 months. There were 43 (61%) successful deliveries, counting a twin pregnancy, 22 natural miscarriages and 6 therapeutic abortions. The rate of premature deliveries was very low (9%) compared to full-term deliveries (91%).

Out of 44 live births (birth weight of 3.1 ± 0.6 kg on an average), 25 (57%) were vaginal deliveries, and 19 (43%) was by C-section. About 7% of females reported retained placenta, 5% with placenta previa and 2% with acute preeclampsia. There were complications reported in newborns during postpartum and breastfeeding, excluding 1 baby born with tetralogy of Fallot.

A healthy and full-term pregnancy can be achieved in females undertaking USgHIFU ablation therapy of uterine fibroids with very few intrapartum or postpartum issues.